Skip to main content

Landos Biopharma, Inc.

LABPDelisted May 23, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001785345

Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.

Q2 2023 vs. Q1 2023

How the institutions holding Landos Biopharma, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of LABP: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders208−12
Shares15.5M1.49M−14.0M (−90.4%)
Value$4.63M$6.27M+$1.64M (+35.3%)

New holders (0)

Institutions that held Landos Biopharma, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

None.

Sold out (12)

Institutions that held Landos Biopharma, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of LABP in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Macquarie Group Ltd147,182$44.0K
Geode Capital Management, LLC91,538$27.3K
Citadel Advisors LLC86,093$25.7K
Renaissance Technologies LLC79,201$24.0K
Warberg Asset Management LLC73,504$21.9K
Bridgeway Capital Management, LLC39,000$11.6K
State Street Corp25,200$7.51K
Vanguard Group Inc23,995$7.15K
Susquehanna International Group, LLP14,976$4.46K
Northern Trust Corp12,219$3.64K
Green Square Capital Advisors LLC10,000$2.98K
Bank of America Corp26$8